comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 00:05:27 - browse：653

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Judge denies Trump's request for new trial in E. Jean Carroll case

focus

Wikipedia

WSS

Humana cuts profit projections as Medicare Advantage costs soar

How a Boston hospital is priming medical residents to use GPT

Caribou posts encouraging results on off

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Medicare Advantage today, explained in one chart

leisure time

comprehensive

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Elizabeth Holmes banned from government health programs

In age of alternative facts, a scholarly course on calling out crap

US jobless claims fall again as labor market continues to flash strength

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Merck, J&J, and long Covid

In age of alternative facts, a scholarly course on calling out crap

'CMA Fest' 2023: How to watch, who is performing and more

Peter Hotez and the public health issue of online harassment

Humana cuts profit projections as Medicare Advantage costs soar

focus

Delta passengers in Vegas fall sick while waiting on flight in triple

Parkinson’s finding may lead to tests and, someday, treatments

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Elizabeth Holmes banned from government health programs

When a patient nears the end, a feared therapy can comfort

The stock market has soared this year, but will it last? Experts weigh in

focus

focus

Wikipedia

hotspot